WIA
ACAD icon

Wealthstreet Investment Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Wealthstreet Investment Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-115,820
Closed -$2.99M – 98
2021
Q1 		$2.99M Sell
115,820
-28,900
-20% -$1.27M 0.29% 80
2020
Q4 		$7.74M Sell
144,720
-1,900
-1% -$94.3K 0.78% 30
2020
Q3 		$6.05M Buy
146,620
+2,250
+2% +$97.2K 0.68% 36
2020
Q2 		$7M Sell
144,370
-3,200
-2% -$154K 0.86% 31
2020
Q1 		$6.24M Buy
147,570
+100
+0.1% +$4.12K 0.92% 30
2019
Q4 		$6.31M Sell
147,470
-170
-0.1% -$7.4K 0.74% 38
2019
Q3 		$6.24M Sell
147,640
-8,640
-6% -$262K 0.8% 37
2019
Q2 		$4.18M Sell
156,280
-3,050
-2% -$77.9K 0.54% 53
2019
Q1 		$4.28M Buy
159,330
+4,000
+3% +$93.4K 0.56% 51
2018
Q4 		$3.43M Sell
155,330
-28,500
-16% -$553K 0.48% 57
2018
Q3 		$3.82M Sell
183,830
-680
-0.4% -$10.7K 0.47% 57
2018
Q2 		$2.82M Sell
184,510
-25,880
-12% -$461K 0.37% 70
2018
Q1 		$4.73M Buy
210,390
+9,930
+5% +$275K 0.59% 42
2017
Q4 		$6.04M Buy
+200,460
New +$6.41M 0.73% 31

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Wealthstreet Investment Advisors's ACAD Position: Q2 2021 in Review

Wealthstreet Investment Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q2 2021, closing a stake of 115,820 shares — an estimated $2.99M sold.

Wealthstreet Investment Advisors first reported a position in ACAD in Q4 2017 and held it in 14 quarters. The position peaked at $7.74M in Q4 2020. 245 funds tracked by Wall St. Rank hold ACAD as of Q2 2021.

  • Wealthstreet Investment Advisors reported no remaining Acadia Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Wealthstreet Investment Advisors sold 115,820 Acadia Pharmaceuticals shares in Q2 2021, an estimated $2.99M.
  • Wealthstreet Investment Advisors first reported a position in Acadia Pharmaceuticals in Q4 2017 and held it in 14 quarters.
  • Wealthstreet Investment Advisors's Acadia Pharmaceuticals position peaked at $7.74M in Q4 2020.
  • 245 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2021.

Based on Wealthstreet Investment Advisors's 13F filing for Q2 2021, filed 2 Aug 2021.